The other major family of anti-BL antibodies bind fl(2---~6) fructosan linkages. These antibodies are more heterogeneous by IEF analysis, although still comparatively simple (16) . The Id identified on the ~(2---~6) fructosan-binding myeloma proteins ABPC48 (A48 or Abl) and UPC 10 are not generally detected in the serum of mice immunized with BL (14) . However, anti-BL molecules expressing the idiotypic determinant(s) of Abl (Abl Id) are part of the repertoire. They are found in the anti-BL antibody response of congenitally athymic (nu/nu) BALB/c mice pretreated with anti-In-IdX antibody, although not in the response of "normal" nu/nu mice (17) .
In the present experiments, we have immunized BALB/c mice with Abl, BALB/c anti-A48 (Ab2), and BALB/c anti-(anti-A48) (Ab3), and have examined the effect of such immunity on the total anti-BL response and on the expression of Ahl in this response. Interestingly, mice immunized with Ab2 that have produced Ab3 express a substantial amount of Abl in their anti-BL response. In contrast, mice producing Ab2 and anti-(anti-[anti-A48]) (Ab4) show a generalized inhibition of the total anti-BL response.
Strikingly, Ab3 expresses idiotypic cross-reactivity with Aba in that Ab4 binds to Abl, and Aba inhibits the binding of radiolabeled Ab3 to Ab,. Although this crossreaction is of relatively low affinity, it is a feature of 60-70% of the Ab3 molecules detected in this assay. This implies that the Id-anti-Id chain is not unidirectional and strongly suggests that immunization with Ab2 causes the production of "Abl-like" molecules (Ab3) because it binds to Abl-like idiotypic determinants on B lymphocytes.
Finally, we have encountered an immunization procedure in which administration of Ab~ to BALB/c mice leads to the production of Ab3. These Ab3-producing mice resemble Ab2-immunized mice in that, upon immunization with BL, they produce antibodies expressing the Abl Id. This suggests that functionally important [d-anti-Id chains may be initiated in the course of "normal" immune responses.
Materials and Methods
Mice. BALB/c AnN mice, 8-12 wk old, were used in this study. Antigens. BL from Aerobacter levanicum (ATCC 1552) was obtained as previously described (14) .
Myeloma Proteins. Abx and UPC10, fl(2---,6) fructosan-binding BALB/e myetoma proteins, and MOPC-384, a Salmonella tranaroa lipopolysaccharide-binding BALB/c myeloma protein, were the gifts of Dr. Michael Potter, National Cancer Institute, National Institutes of Health, Bethesda, Md. Aba and MOPC-384 are IgA, K-proteins; UPC10 is an IgG2a, K-protein.
Preparation ofAnti-ld Antisera. Ab2 antisera were prepared in A/He mice by immunization with Ab~ myeloma protein and in BALB/c mice by immunization with an AbI-keyhole limpet hemocyanin (KLH) conjugate. Ab3 antiserum was prepared in BALB/c mice by immunization with a KLH conjugate of affinity chromatography-purified BALB/c Ab2 Id antibody. Similarly, Ab4 antiserum was prepared by immunization of BALB/c mice with a KLH conjugate of purified BALB/c Aba antibody. Purification of antibodies on Sepharose 4B-anti-Id columns, coupling of affinity chromatography-purified antibodies to KLH, and immunization schedules are as previously described (18) .
Preparation of Coupled Sheep Erythrocytes (SRBC).
An O-steroyl derivative of BL was prepared according to the technique of HS.mmerling and Westphal (19) and then coated to SRBC as previously described (14) . SRBC were coated with myeloma proteins and various affinity chromatography-purified antibodies by the chromic chloride method, using a concentration of 0.6-1.0 mg/ml of appropriate protein.
Determination of Hemagglutinin (HA) Titers. HA titers of antibodies specific for BL and for Id were determined in microplates by using SRBC coated with O-steroyl BL, myeloma proteins, or affinity chromatography-purified antibodies. The titer recorded is 1/log2 of the highest dilution of antisera giving agglutination.
Determination of Serum
Id. An HA-inhibition (HI) method described previously (13, 14) was used to test sera for the presence of Id. The Abl Id was studied by using both A/He and BALB/c Ab2 antisera and Abrcoated SRBC. BALB/c Ab3 antisera and affinity chromatography-purified Ab2 antibody-coated SRBC were used to detect Id of Abz antibodies. BALB/c Ab4 antisera and affinity chromatography-purified Ab3 antibody-coated SRBC were used to detect Id of Aba antibodies.
Radioimmunoassay (RIA).
Purified Aba antibodies and Abl myeloma protein were tritiated according to the method of Wilder et al. (20) . Aba antibodies were labeled with izsI by the chloramine T method (21) . The ability of BL to bind to aH-Abl myeloma protein was determined in mierotiter plates that had been incubated for 18 h with 50 pg BL, followed by three washings with saline. The plates were incubated for 1 h with 50% fetal calf serum (FCS) and, after three washings, incubated for 3 h with SH-Abl (10,000 cpm/50 #l). The ability of allAbl, aH-Aba, and 125I-Aba to bind Ab2 antibodies or Ab4 immunoglobulin (Ig) was determined with the use of microplates that had been incubated with various amounts of purified Ab2 antibodies or with the Ig fraction of Ab4 antiserum for 18 h at 4°C. After washing and incubation with 50% FCS as described above, the plates were incubated for 3 h with 3H-Abl, aH-Aba (~5,000 cpm/50 #1), or ~2~I-Aba (39,000 cpm/50 bd). To determine the capacity of various proteins or sera to inhibit the binding of radiolabeled Ab3 antibodies or of 3H-Abl to Ab2 or Ab4, plates coated with Ab2 antibodies or with Aba Ig were incubated for at least 3 h with various dilutions of inhibitor and washed before the addition of radiolabeled antibodies (22) . Radioactivity on plates was measured in a liquid-scintillation spectrometer.
Plaque-forming Cell (PFC) Assay. The number of PFC-secreting antibodies specific for BL was determined according to a previously described technique (13) . PFC secreting anti-BL antibodies carrying the Abl Id were enumerated by the addition of BALB/c (1:300) or A/He (1:150) anti-A48 Id antisera to agarose, The number of PFC obtained in the presence of these sera was subtracted from that obtained if no inhibitory serum was present to give the number of Aba Id + anti-BL PFC.
Results

Characterization of Id.
A series of anti-Id antibodies mimicking an Id-anti-Id chain, or pathway, comprising Ab2, Ab3, and Ab4 antibodies was induced by immunization of syngeneic mice with KLH conjugates ofAbx, Ab2, and Abz antibodies, respectively. The presence of these anti-Id antibodies was determined by HA and RIA assays. Thus, Ab2 antiserum agglutinated both AbrSRBC and Abz-SRBC (Table I) . The Abx-SRBC agglutinating activity of Ab2 antiserum was completely removed by The antiserum containing Ab4 antibodies agglutinated Abs-SRBC, as expected. However, it also agglutinated Aba-SRBC. Interestingly, the capacity of Ab4 serum to agglutinate AbrSRBC was completely removed by absorption with Aba-Sepharose beads but only partially removed by Abl-Sepharose beads (Table I ). These results indicate that Ab4 can bind to Abl but suggest that this binding is of relatively low affinity. To study this in greater detail, we examined the binding of 125I-Ab3 by both Abz-and Ab4-coated microplates and compared this with the binding of aH-Abl by similar microplates (Table II) . We observed that 12SI-Aba and aH-Aba bound to both Ab2 and Ab4 plates. Controls using BALB/c Ig and Aba plates indicated the specificity of this binding. The ratio of amount of aH-Abl bound by the Ab4 and Ab2 plates and the ratio of ~I-Ab3 bound by these plates were similar. Because all Aba and Ab3 molecules should be specific for Ab2, the similarity of this ratio suggests that the fraction of the Aba molecules specific for Ab4 is similar to the fraction of Abs molecules specific for Ab4. Furthermore, Abl can inhibit the binding of 60-70% of radiolabeled Ab3 to Ab4 plates. Control proteins such as MOPC-384 and UPCI0 cause little or no inhibition. One such inhibition experiment is illustrated in Fig. 1 . Comparable results have been obtained in three additional experiments, using aH-Aba as well as 125I-Aba.
The relative affinity of Ab4 for Abl can be estimated from the concentration of Abl required to inhibit binding of lzSI-Abs or of aH-Abt to Ab4 microplates (Table III) . We found that 2.2 pg/ml of Abl was needed to inhibit 50% of the binding of 12SI-Aba to Ab4 plates, whereas only 0.006 ~g/ml of Aba was needed for comparable inhibition. This suggests that Ab4 binds to Aba with substantially greater affinity than it binds to Abl. On the other hand, a concentration of 0.03 pg/mt of Abl was sufficient to inhibit 50% of the binding of 3H-Abl to Ab4 microplates. This is consistent with a relative affinity of the binding of Ab4 to Abe, which is greater than that indicated by Aba inhibition of binding of Ab4 to Ab3 plates, although still lower than the relative affinity of binding of Ab4 to Aba. At this time, we cannot fully reconcile these differing estimates of the relative affinity of Ab4 for Abl.
The interactions of these anti-Id antibodies were also studied by an HI assay. The agglutination of Abl SRBC by A/He and BALB/c Ab2 was inhibited by Abl myeloma protein (Table IV) . The agglutination of Abrcoated SRBC by BALB/c Ab2 antibod- cpm bound after addition of inhibitor -cDm bound to control plate.~ % inhibition = 100 1 -
Control plates for aH-Aht were coated with BALB/c Ig and with Abz Ig; control plates for t25I-Aba were coated with BALB/c lg. The cpm bound to control plates and to Ab2 and Ab4 plates are presented in Table II . (Table IV) . The inhibitory ability of BALB/c Ab2 was shared by BAB. 14 and C.B20 Abz antibodies but not by A/He and AL/N antibodies (data not shown). 
The agglutination of Aba-SRBC by Ab4 was inhibited by Aba, as anticipated. In addition, it was inhibited by high concentrations of Aba. This is similar to the finding that relatively high concentrations of Abl are required to inhibit the binding of radiolabeled Aba to Ab4-coated plates. Both results indicate that Ab4 recognizes Aba and Abl, although its affinity for Abl is lower than that for Aba.
The Ab2, Aba, and Ab4 antisera did not react with BL to any greater extent than did normal serum (Table V) . The low anti-BL HA titer of these antisera and of the sera of normal nonimmunized BALB/c mice presumably represents the presence of "natural" anti-BL antibodies due to immunization with environmental antigens (22, 23) . This phenomenon is common for several polysaccharide antigens borne by saprophytic intestinal flora.
These results indicate that through intentional immunization a set of complementary anti-Id antibodies can be produced and that each differs from the others. In particular, Aba differs from Abl in that it lacks the capacity to agglutinate BL-SRBC (Table V) and to bind to BL-coated plates (data not shown). Ab4 differs from Ab2 in that its ability to agglutinate AbI-SRBC is ineffectively removed by Abl-Sepharose and its ability to bind both radiolabeled Ab3 and Aba-SRBC requires high concentrations of Aba for inhibition. Nonetheless, this analysis indicates that the majority of Aba molecules express an IdX which cross-reacts with an Id found on Abl. This result is quite unexpected in a "linear" Abl-Ab.i2-Aba-Ab4 system, but is comparable to a previous result of Wikler et al. (24) in a similar rabbit system.
Immunization with Abl Causes the Production of Aba. The previous experiments demonstrate the characteristics of members of an Id-anti-Id chain induced by intentional immunization with a KLH conjugate of the immediately preceding member of that chain. In order to determine whether the chain normally develops beyond the first step after immunization with native Abl, we immunized BALB/c mice with Aba, using two different protocols, and tested for the appearance of both Ab2 and Abs.
One group of seven mice was immunized eight times with Abl not conjugated to KLH. The immunization protocol consisted of an initial immunization in complete Freund's adjuvant (CFA), followed by one immunization in incomplete Freund's adjuvant (IFA), and then by six weekly immunizations in saline. These mice were bled weekly after the completion of the entire protocol. Each of the mice of this group made Ab2, which was found over an 8-wk period after completion of immunization. Aba was not detected in any of these mice during this period (Fig. 2) .
In five of the mice of this group, the Ab2 observed differed from the Ab2 found in BALB/c mice after immunization with Abl conjugated to KLH (see Table I ). The Ab2 of these five mice failed to agglutinate Aba-SRBC. In two of the seven mice, the sera could agglutinate both Abx-SRBC and Abs-SRBC, although the titers varied substantially during the 8-wk period. Furthermore, these two mice may also have produced Ab4. We suggest this because adsorption of their sera with Abl-Sepharose only partially removed the ability to agglutinate Abs-SRBC, whereas absorption with Aba-Sepharose removed it completely (Table VI) .
A second group consisting of four mice was immunized twice with Aba, once in CFA and once in IFA. These mice expressed a low serum titer of hemagglutinating Ab2 antibodies 1 wk after the completion of immunization (Fig. 3) . By 3 wk after completion of immunization, three of these mice had no detectable Ab2 serum titer and one mouse had a very low titer in its serum. At this time, each of these mice displayed a significant Abs titer. By 5 wk, the Abs titer had fallen in all but one of the mice and was replaced by Ab2, but by 8 wk, Abs was again found in the absence of detectable Ab2. Thus, mice immunized in this way with Abl show a prompt appearance of Ab2 and then show an inverse fluctuation in Ab2 and Abs levels. However, we have not examined the second peak (at 5 wk) of Ab2 HA activity to determine whether it represents an Ab2 or Ab4, or a mixture of Ab2 and Ab4.
Our data indicate the appearance of auto-Aba and possibly of auto-Ab4 in mice immunized with Abl. This is consistent with the development of an extended chain of anti-Id reactions in individual animals.
Activation of Abl Id ÷ Anti-BL Precursors in Mice Immune to Abe. Normal BALB/c mice, as well as BALB/c mice that had been immunized with Ab2 Id antibodies, have low serum anti-BL HA titers and a small number of anti-BL PFC (Table VII) . No Abt * Sera from two mice that produced Ab~ antibody that agglutinated Aba-SRBC were tested. :~ Serum (0.2 ml) was adsorbed with 0.1 ml of Sepharose 4B beads to which the indicated protein had been conjugated. Id + antibodies could be detected by either HI, RIA, or PFC assays in these mice.
Immunization with BL leads to the development of a significant titer of anti-BL antibodies and anti-BL PFC. As we have previously shown, Abl Id + anti-BL antibodies are not detected in this response (17) . BALB/c mice that had been immunized with Ab2-KLH developed a vigorous response upon immunization with BL, and a substantial fraction of their anti-BL antibodies expressed the Abl Id. Immunized mice producing Ab2 (and possibly Ab4), as a result of immunization with Abl using the eight-injection protocol, developed an anti-BL response of lower magnitude than did normal mice immunized with BL. They failed to express Abx Id. In contrast, mice that had produced Aba as a result of immunization with Abl using the two-injection protocol expressed a marked increase in their total anti-BL response and developed a considerable amount of Abl Id ÷ anti-BL antibodies upon immunization with BL. Thus, in these animals, the presence of immunity to Ab2 before immunization with BL was associated with the expression of the Abl Id in the anti-BL response. In contrast, the presence of Ab2 itself was associated with a failure of expression of Abl Id and a decrease in the total anti-BL response. Further, we examined the kinetics of the response to BL of mice producing Ab2, Abz, and Ab4 as a result of immunization with KLH conjugates of Abl, Ab2, and Ah3, respectively. As noted above, Ab2 mice immunized with BL developed a lower anti-BL response compared to BL-immunized normal BALB/c mice. The titer in such Ab2 mice did not approach normal levels until 20 d after immunization (Fig. 4) . Ab3 mice immunized with BL exhibited a total anti-BL response quite similar in amount to that of normal mice. Most interestingly, Ab4 mice showed a degree of suppression of their total anti-BL response that was at least as profound as that of Ab2 mice. These results suggest that Ab2 and Ab4 express a functional similarity and reinforce serologic evidence that indicates that Ab4 resembles Ab2 in that it binds Abe.
Discussion
Our results demonstrate that a chain of complementary anti-Id antibodies comprising four members (Abl, Ab2, Ab3, and Ab4) can be generated by immunization of syngeneic mice with KLH conjugates of the immediately preceding member of the chain. Thus, these results formally demonstrate that in syngeneic animals an extended Id-anti-Id regulatory system is possible. A similar four-member chain (Abl-Ab4) has been described by Wikler et al. (24) in allotype-matched rabbits, and three-member chains (Abl-Ab3) have been described previously in syngeneic mice (18) and allotypematched rabbits (10) . We observed that immunization with unconjugated Abl, under certain circumstances, leads to the occurrence of auto-Ab3, as well as auto-Ab2. Furthermore, our results suggest that such immunization may occasionally lead to the production of auto-Ab4. These observations indicate that the chain developed by stepwise immunization with KLH conjugates can be observed under normal conditions. Prior evidence that initial events in chain formation occur has been obtained. Thus, it has been reported that the immunization with conventional antigens leads to the occurrence of auto-anti-Id antibodies (25) (26) (27) , auto-anti-Id PFC (13, 28) , and auto-anti-Id-binding cells (29) (30) (31) . Naturally occurring Id-specific T cells (2), as well as Id-specific T cells generated after immunization with Id-bearing antibodies (30, 32) , with Id-bearing antibodies coupled to syngeneic cells (31, 33) , or with anti-Id antibodies (30, 34) , have also been described.
The presence of immunity to Abl, Ab2, or Ab~ in mice has a significant effect on the amount and nature of the antibody response to BL, which is the antigen that is the putative initiator of the Id-anti-Id chain. Thus, in mice that have produced Ab3, either because of immunization with KLH-Ab2 or after responses to Abl, we observed that the primary response to BL contained a major fraction of antibodies that express the Abl Id. This Id is not detected in the response to BL of normal or nu/nu mice of the Igh a type, nor is it found in the response of intact BALB/c mice that have been pretreated with antibody to the In-IdX (35) . The only previous situation in which we observed the appearance of measurable amounts of the Abl Id in anti-BL antibodies was in the response to BL of nu/nu BALB/c mice that had previously been treated with anti-In-IdX (17) . If such mice are given T lymphocytes at the time of BL immunization, the Abl Id is not observed in their antibody response. This suggests that the expression of Abl Id is under some type of T lymphocyte-dependent control and that the Ab~ Id is probably not a major member of the anti-BL repertoire, because suppression of the anti-B(2--~ 1) component of the anti-BL response is required for its expression even in the absence of T cells.
In this context, it is interesting to consider why immunity to Ab2 should lead to the development of an Abl Id ÷ anti-BL response. One obvious possibility is that Ab3, which is anti-(anti-A48Id), could eliminate suppressor T lymphocytes that express Ab2 (anti-A48Id) specificity. Indeed, we have shown in the MOPC-460-trinitrophenyl (TNP) system that mice immunized with Ab2 (anti-MOPC-460) lack 460Id-specific suppressor T cells, which are found in normal mice and which regulate the activation of the precursors of 460Id ÷ anti-TNP antibody-secreting cells (12) . However, if elimination of suppressor T cells specific for Abl Id (i.e., Ab2-bearing suppressors) is the only reason that immunity to Ab2 leads to expression of Abl, one might anticipate that nu/nu mice immunized with BL would express substantial Aba Id in their anti-BL response. As we noted above, this is not the case. A second possibility is that Ab3 could be regarded as consisting of the entire set of antibodies that can react with Ab2. Because Abz is anti-A48Id, Ab3 would be expected to include Aba. However, mice immunized with Ab2-KLH, but not with BL, have no greater anti-BL serum antibody titer than do normal mice. Thus, Abl cannot be a very important component of Ab3. Nonetheless, precursors of Abl (i.e., A48Id + anti-BL) antibody-secreting cells appear to have been primed by immunization with Ab2, because BL immunization leads to their activation and to the appearance ofAb~ Id in the anti-BL response of Ab2-KLH primed mice, and of those Abl-immunized mice that produced Aba. It seems likely to us that both of these mechanisms contribute to the regulation of the Abl Id + anti-BL response in mice that have produced Ab3.
One of the most interesting results to emerge from these studies and those of Wikler et al. (24) is the apparent asymmetry of the chain of anti-Id. Thus, we observed that Ab, resembles Abe in that both bind to Abl and to Abz, and that both lead to a suppression of anti-BL antibody response. Although Ab4 and Ab2 are not identical, because their affinities for Abl are different, it is particularly important to note that the majority of the Ab4 molecules tested in our assays bind Abl. This was shown by the fact the Abl inhibited the binding of >60% of radioactive Ab3 by an Ab4 plate and by the capacity of high concentrations of Abl to inhibit hemagglutination of Ab3-SRBC by Ab4. In contrast, Abs and Abl differ in that Ab8 fails to recognize BL, whereas Abl is a BL-binding myeloma protein. In the studies of Wikler et al. (24), a four-member chain was initiated with antibody to the polysaccharide from Micrococcus lysodeikticus. In these experiments, Ab4 and Ab2 both bound to Abl, but Aba failed to bind to M. lysodeikticus polysaccharide antigen.
It is possible that the chain is only seemingly asymmetrical and the appearance of asymmetry is due to a relatively low affinity of Abl for the polysaccharide antigens (BL and M. lysodeikticus polysaccharide) used in these systems. If Aba were cross reactive with Abl but had an energy of binding which was 1 or 2 kcal lower than Abe, it might fail to bind antigen under the conditions used. In contrast, it is likely that the Ab2-Abl interactions, representing antibody-protein antigen interactions, are of relatively high affinity, and that the binding by cross-reactive Ab4 would be detectable even if the energy of interaction of Ab4 for Abl was considerably less than that of Ab2 for Abl. In fact, there are three reported instances of Ab3 displaying some Abl-like antigen-binding activity. These are in systems in which the initiating antigens are insulin-binding receptor (36) , retinol-binding receptor (36) , and tobacco mosaic virus capsid protein (37) . However, our observation that the majority of Ab4 molecules bind Ab~ suggests that this is an important feature of Id-anti-Id chains.
Consequently, we wish to suggest an explanation for the observed lack of symmetry in this chain of anti-Id which represents a distinctive view of the Id-anti-Id regulatory system. In considering this proposal, we first wish to outline what we believe to be a major difficulty in certain of the network concepts. In the most simplified and extreme case, one imagines a physiologic network to be initiated by the antibody produced in response to antigenic determinants. Such antigenic determinants, in accordance with the Jerne nomenclature, are termed epitopes (7). Anti-epitope antibodies (Abl) express Id that are currently recognized to actually consist of a series of distinctive determinants located on different portions of the variable region. These individual idiotypic determinants have been designated idiotopes. Because each Abl may express at least two and probably several idiotopes (38) , there should be at least two and probably several Ab2 generated in response to each Abl (39) . Similarly, each Abz should stimulate the appearance of several Ab3 and each of these, in turn, should stimulate the appearance of several Ab4. This would suggest that the number of distinct molecules in the set of Ab2, Ab3, ... Abn antibodies must be very much larger than the set of distinct Abi antibodies, and that the bulk of the antibody repertoire is devoted to recognition of idiotopes. This concentration on idiotopes might be more illusory than real if most anti-idiotope antibodies also recognized some epitope, presumably because of a structural similarity between the particular idiotope and the particular epitope (40) . Thus, the set of anti-idiotope antibodies and anti-epitope antibodies would be the same set. This concept, in its extreme form, is tenable only if the expressed idiotopes of Ig cross-react with virtually every possible antigenic determinant, including polysaccharides, lipids, and simple organic haptens. We regard this as quite unlikely in chemical terms. A second finding not well explained by linear or expanding idiotope-anti-idiotope chains is the capacity of Ab4 to bind Abl.
We wish to propose a very different idea to explain idiotope-anti-idiotope interactions (Fig. 5 ). In our model, the set ofanti-epitopes (Abl) and anti-idiotopes (Ab2) are functionally distinct. Thus, we suggest that, although antibodies to conventional antigenic determinants bear many idiotopes, only a limited number of these idiotopes function in eliciting responses in autologous or syngeneic animals. We designate such determinants "regulatory idiotopes." Thus, the anti-idiotope antibodies that develop in autologous or syngeneic systems will be directed to a limited number of determinants. It should be obvious that Ab2 idiotopes will be similar to each other in that each binds the Abl Id. They may be sufficiently heterogeneous to display a large number of regulatory idiotopes, each expressed on only a small fraction of the Abz molecules. Alternatively, the set of Abe may differ from the set of Abl in that it fails to express regulatory idiotopes. In either case, intentional or natural immunization with Ab2 will be relatively efficient in activating those B cells that bear the regulatory idiotopes for which Ab2 is specific (the Abl regulatory Id), but will cause limited induction of anti-Abz, either because no single Ab2 Id is present at sufficiently high concentration to stimulate anti-Id antibodies, or because Ab2 molecules do not display regulatory Id. Therefore, for purposes of immunization, Ab2 functions mainly as an anti-Id antibody rather than as an antigen. The antibodies raised against Ab2 should resemble each other in that each will express the Abl regulatory idiotope or determinants that cross-react with this idiotope. We suggest that the number of such idiotopes is relatively small and that antibodies of very different specificities may share cross-reactive regulatory idiotopes. Thus, Ab3 should more correctly be regarded as a collection of molecules possessing the Abl-type regulatory idiotope (i.e., Abl, Abl' ... Abln), of which Abl will be only one member of a relatively large family. Thus, the antigen-binding activity of Ab3 might be difficult to detect. On the other hand, immunization with antigen (e.g., BL) should reveal that Abl-bearing epitopespecific precursors have been "primed" by Ab2 immunization. That is, Abl should be represented in the anti-epitope response to a larger extent than in animals not immunized with Ab2. When Aba antibodies are used in immunization, the resultant Ab4 should bind Abl because Abl and Aba express cross-reactive regulatory idiotopes. Thus, Ab4 should be similar to Aba, because both are directed against the Aba regulatory idiotope. This model is consistent with several findings that have been reported previously. First, the concept that in syngeneic immunizations only the regulatory idiotopes are antigenic is consistent with the Lieberman-Potter rule (42) . This states that it is much more difficult to produce anti-Id antibodies against myeloma proteins when the mouse immunized is of the same Igh-C type as the donor of the myeloma protein than when the immunized animal and the donor are of different lgh-C types. Second, the concept that Aba consist of molecules bearing idiotopes cross-reactive with Abl but that the serum of Ab3 mice has little antigen (e.g., BL)-binding activity is consistent with reports that Id, such as the A5AId, may be found on molecules capable of binding a given antigen (e.g., Streptococcus A carbohydrate), as well as molecules that have no detectable capacity to bind that antigen (43) .
Obviously, a model of this sort is best stated in extreme terms both for ease of description and precision of predictions. Nonetheless, one must consider certain problems. First, Ab4 binds Ab3 with much higher affinity than it binds Abl. Thus, the Aba family (i.e., those molecules that bear regulatory idiotopes cross-reactive with that of Abl) must be moderately heterogeneous. For simplicity, one would prefer a very limited degree of heterogeneity in the Abl idiotope. However, this heterogeneity might be explained by influences on the conformation of the regulatory idiotope by the structure of other portions of the hypervariable regions. Second, we demonstrated that Abl could inhibit the binding of 60-70% of radioactive Ab3 to Ab4 plates. This suggests that a fraction of the Abn molecules may lack the Abl regulatory idiotopes, and that immunization with Ab2 actually elicits some anti-Ab2 antibodies. However, it should be pointed out that the immunization scheme, involving Ab2-KLH conjugates, is not physiologic and may allow responses to idiotopes not normally immunogenic in spontaneous autoimmunization.
Finally, one might speculate about whether regulatory idiotopes are a feature of all anti-epitope antihodies (i.e., all Abl) or only of a subset of Abl. In particular, regulatory idiotopes might be a feature only of those Abl idiotopes that are capable AUTO Abs AND SILENT CLONES of becoming dominant Id, possibly because it is these determinants that call forth Idspecific T cell regulatory responses, as well as anti-idiotope (Ab2) antibodies. Indeed, Abl bearing anti-BL antibodies appear to be under the regulatory control of T lymphocytes because their expression in the anti-BL response of nu/nu BALB/c mice, pretreated with antibody to the IdX of anti-In, is inhibited by T lymphocytes. Thus, if the number of distinct regulatory idiotopes is relatively small, the existence of relatively large clones of regulatory T lymphocytes specific for these idiotopes might explain the powerful effects of Id-determined T lymphocyte regulation which have been increasingly observed in recent years.
Finally, this anti-epitope-anti-idiotope concept or, more simply, this +,-concept of the Id-anti-Id regulatory system does have some network features in that many apparently unrelated Abt idiotopes can be affected by the action of a single Ab2. However, in the model we propose, the effect of a single Abx-Ab2 system (i.e., the a Abl-a Ab~ system) should be limited to the Abl possessing a common regulatory idiotope (the a Abl idiotope) and as such should be relatively isolated from other AblAb2 systems (e.g., the b Abl-b Ab2, c Ahl-c Ab2, . . .z Abl-z Ab2 systems) (Fig. 5) . One might describe this system as a "ping-pong" effect, in which the Abx side has many players and the Ab2 side has few. Summary BALB/c mice immunized multiple times with ABPC48 (A48 or Abl), a BALB/c bacterial levan (BL)-binding myeloma protein, produce anti-Abl antibodies (Ab2). Immunization with only two doses of Aba often leads to the production of anti-(antiA48) (Abs) as does immunization with hemocyanin conjugates of Ab2. Finally, immunization with hemocyanin conjugates of Ab3 leads to the production of anti-(anti-[anti-A48]) (Ab4). Normal BALB/c mice immunized with BL produce an anti-BL antibody response containing no detectable Abt idiotype (Id)-bearing molecules. Mice producing Ab3 express substantial amounts of Abl Id in their anti-BL response whereas mice producing Ab2 and Ab4 show a generalized inhibition in their anti-BL response. These results indicate that states of immunity within an idiotypic chain may have marked effects on antibody responses to the antigen (i.e., BL) which is the putative initiator of the chain. Strikingly, the chain itself has an interesting feature. That is, Aba and Aba share a cross-reactive Id in that both are bound by Ab4 and Ab2. We propose a model of Id-anti-Id systems to explain this unexpected result. This is based on the concept of regulatory idiotopes on Abl molecules which initiate Ab2 (anti-idiotope) responses. In contrast, Ab2 molecules generally fail to initiate anti-Abz Id responses either because any individual idiotope is present at very low concentration or because Ab2 molecules tend to lack regulatory idiotopes. Thus, Ab2 molecules immunize syngeneic animals because they interact with cells bearing Ab1-1ike regulatory idiotopes. Thus, Aba will share regulatory idiotopes with Aba. Ab4 and Ab2 will share the ability to bind the Abl-like regulatory idiotope.
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